* South Africa expecting 7 mln Pfizer (NYSE: PFE ) doses by June
* Study suggested variant may reduce protective antibodies
* Advisers say vaccine still good fit for country
* S.Africa worst-affected by pandemic on continent (Adds Abdool Karim, context, detail)
By Alexander Winning
JOHANNESBURG, Feb 19 (Reuters) - Two of the South African government's top advisers on COVID-19 backed Pfizer's vaccine on Friday, despite a study earlier this week showing that the dominant local coronavirus variant may reduce protective antibodies it triggers.
The country is counting on the Pfizer PFE.N shot, developed with German partner BioNTech 22UAy.DE , to step up its vaccination programme after administering its first Johnson & Johnson (NYSE: JNJ ) JNJ.N doses on Wednesday. AZN.L vaccinations are on hold after a small local trial found the shot offered minimal protection against mild to moderate illness from the 501Y.V2 variant first identified late last year. laboratory study published in the New England Journal of Medicine suggested that the 501Y.V2 variant may reduce protective antibodies elicited by the Pfizer vaccine by two-thirds. scientists were quick to caution that because the study's findings were from a lab it was difficult to judge what they might mean in the real world.
Professor Barry Schoub, chairman of the Ministerial Advisory Committee on vaccines, told Reuters the two-thirds reduction in antibodies mentioned in the study "means there is quite a significant remnant neutralising potency, ... we feel Pfizer is still a very good vaccine in our context".
The advisory committee held its regular weekly meeting on Thursday and discussed the study.
While it has not been established in a clinical trial that the Pfizer vaccine protects against the more contagious 501Y.V2 variant, "we can have a reasonable extrapolation because it's such a potent stimulator of the immune system", Schoub said, adding that authorities would monitor closely those who get the Pfizer vaccine.
Health Minister Zweli Mkhize said on Wednesday that South Africa was expecting 500,000 doses of the Pfizer vaccine initially and about 7 million doses by June.
'WITHIN TOLERABLE LIMITS'
Professor Salim Abdool Karim, another government adviser, said in a separate interview that the reduction in neutralising activity identified in the study was "within the tolerable limits of what we can accept".
Importantly, he said, it was not yet established that antibodies against the spike protein that the virus uses to infect human cells correlate with protection.
"It is one of many hypotheses that are currently being investigated," he said, adding: "We do not know what it is in these vaccines that's leading to protection."
Asked whether he would recommend pausing Pfizer vaccinations for now, he said: "No, in fact the opposite. This is within our tolerable limits of neutralisation."
He said there was little point in doing a clinical study to further test the Pfizer vaccine against the local variant because it was already being adapted with a 501Y.V2 insert. "So if we had to start a clinical study, by the time we get the results they will already have their new vaccine," he continued.
South Africa, with nearly 1.5 million cases and over 48,000 deaths, has recorded almost half the COVID-19 fatalities and over a third of confirmed infections in Africa.
It lagged richer nations in launching its immunisation campaign.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.